You are here: Industry Insights > Buyout

News List

AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last? fiercepharma
August 07, 2019
An enduring medical aesthetics franchise, led by wrinkle-fighter Botox, is one of the key reasons AbbVie is shelling out $63 billion for Allergan. That drug has again pulled off a sales jump, though a slower growth rate suggests a tough game ahead.
PRA buys out Takeda JV, cements outpost in Japan fiercepharma
August 04, 2019
The buyout closed June 1. The move will grow PRA’s staff in Japan to 450 “with opportunity for additional growth in the near term,” the CRO said in a statement last week.
Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout fiercepharma
December 18, 2018
With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous journey.
Horizon Discovery rejects Abcam’s ‘highly opportunistic’ £270M buyout bid fiercebiotech
May 04, 2018
Horizon Discovery has rejected a £270 million ($367 million) takeover bid from Abcam. The gene editing specialist issued a strongly-worded rebuttal of the offer after Abcam went public with its plan...
Takeda’s hard-won Shire deal and Nektar I-O pact; Daiichi’s DMD flop fiercepharma
April 28, 2018
It took five tries, but Takeda has finally reached a preliminary buyout deal for Shire. Investors don't seem all that keen on it...
Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue ne fiercebiotech
August 11, 2017
Celgene gained the Sutro buyout option after paying $95 million and committing to $1 billion more in 2014.